Cara Historical Income Statement
| CARA Stock | USD 0.31 0.01 3.33% |
Historical analysis of Cara Therapeutic income statement accounts such as Interest Expense of 1 M, Selling General Administrative of 15.7 M or Other Operating Expenses of 79.1 M can show how well Cara Therapeutic performed in making a profits. Evaluating Cara Therapeutic income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Cara Therapeutic's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Cara Therapeutic latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Cara Therapeutic is a good buy for the upcoming year.
Cara |
About Cara Income Statement Analysis
Cara Therapeutic Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Cara Therapeutic shareholders. The income statement also shows Cara investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Cara Therapeutic Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Cara Therapeutic. It is also known as Cara Therapeutic overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Operating Income
Operating Income is the amount of profit realized from Cara Therapeutic operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Cara Therapeutic is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.Cost Of Revenue
Cost of Revenue is found on Cara Therapeutic income statement and represents the costs associated with goods and services Cara Therapeutic provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.Most accounts from Cara Therapeutic's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Cara Therapeutic current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cara Therapeutic. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Cara Stock refer to our How to Trade Cara Stock guide.At present, Cara Therapeutic's Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Total Other Income Expense Net is expected to grow to about 3.1 M, whereas Depreciation And Amortization is forecasted to decline to about 246.1 K.
| 2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 112.1M | 122.1M | 142.5M | 78.5M | Cost Of Revenue | 1.6M | 7.3M | 6.2M | 5.9M |
Cara Therapeutic income statement Correlations
Click cells to compare fundamentals
Cara Therapeutic Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Cara Therapeutic income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 370K | 198K | 1.0M | 248K | 259K | 246.1K | |
| Selling General Administrative | 17.7M | 21.7M | 29.4M | 30.3M | 27.6M | 15.7M | |
| Other Operating Expenses | 131.6M | 129.7M | 112.1M | 129.4M | 142.5M | 79.1M | |
| Operating Income | (111.7M) | 5.4M | (89.1M) | (87.5M) | (121.5M) | (115.4M) | |
| Ebit | (111.7M) | 4.6M | (89.1M) | (87.5M) | (117.9M) | (112.0M) | |
| Research Development | 113.8M | 107.9M | 82.7M | 91.9M | 108.5M | 62.2M | |
| Ebitda | (111.5M) | 5.6M | (88.8M) | (87.3M) | (117.7M) | (111.8M) | |
| Cost Of Revenue | 113.8M | 107.1M | 1.6M | 7.3M | 6.2M | 5.9M | |
| Total Operating Expenses | 131.6M | 129.7M | 112.1M | 122.1M | 142.5M | 78.5M | |
| Income Before Tax | (107.2M) | 7.7M | (88.4M) | (85.5M) | (118.5M) | (112.6M) | |
| Total Other Income Expense Net | 4.5M | 2.3M | 642K | 2.1M | 3.0M | 3.1M | |
| Net Income | (106.4M) | 8.4M | (88.2M) | (83.4M) | (118.5M) | (112.6M) | |
| Income Tax Expense | (816K) | (691K) | (248K) | (2.1M) | 91.1K | 95.7K | |
| Total Revenue | 19.9M | 135.1M | 23.0M | 41.9M | 21.0M | 25.2M | |
| Gross Profit | 19.9M | 28.0M | 23.0M | 34.6M | 14.8M | 14.2M | |
| Net Income From Continuing Ops | (106.4M) | 8.4M | (88.4M) | (85.5M) | (116.5M) | (110.7M) | |
| Net Income Applicable To Common Shares | (106.4M) | 8.4M | (88.4M) | (85.5M) | (76.9M) | (80.8M) | |
| Tax Provision | (204K) | (389K) | (816K) | (691K) | (255K) | 0.0 | |
| Non Operating Income Net Other | 4.5M | 2.3M | 642K | 2.1M | 2.4M | 2.0M | |
| Reconciled Depreciation | 370K | 198K | 209K | 248K | 238K | 229.3K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Cara Therapeutic offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cara Therapeutic's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cara Therapeutic Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cara Therapeutic Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cara Therapeutic. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Cara Stock refer to our How to Trade Cara Stock guide.You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cara Therapeutic. If investors know Cara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cara Therapeutic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.75) | Revenue Per Share 0.202 | Quarterly Revenue Growth (0.86) | Return On Assets (0.63) | Return On Equity (1.84) |
The market value of Cara Therapeutic is measured differently than its book value, which is the value of Cara that is recorded on the company's balance sheet. Investors also form their own opinion of Cara Therapeutic's value that differs from its market value or its book value, called intrinsic value, which is Cara Therapeutic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cara Therapeutic's market value can be influenced by many factors that don't directly affect Cara Therapeutic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cara Therapeutic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cara Therapeutic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cara Therapeutic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.